|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0087111,
umls-concept:C0144576,
umls-concept:C0175668,
umls-concept:C0205179,
umls-concept:C0205210,
umls-concept:C0220656,
umls-concept:C0278502,
umls-concept:C0282460,
umls-concept:C0814225,
umls-concept:C0871261,
umls-concept:C1334988,
umls-concept:C1704242,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-3-15
|
|
pubmed:abstractText |
Paclitaxel has shown promise against advanced gastric cancer and associated malignant ascites with non-measurable lesions. In order to evaluate the therapeutic effect of paclitaxel against malignant gastric ascites, a prospective phase II clinical trial was designed according to our previously proposed criteria represented by the clinical benefit response in gastric cancer (CBR-GC) criteria and the five-point method (5PM).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1436-3291
|
|
pubmed:author |
pubmed-author:IishiHiroyasuH,
pubmed-author:ImamotoHaruhikoH,
pubmed-author:KakutaniChiekoC,
pubmed-author:MorimotoTakashiT,
pubmed-author:MoritaSatoshiS,
pubmed-author:NakamuraMasakiM,
pubmed-author:NaraharaHiroyukiH,
pubmed-author:ObaKojiK,
pubmed-author:OriuchiNoboruN,
pubmed-author:SakamotoJunichiJ,
pubmed-author:ShiozakiHitoshiH,
pubmed-author:YumibaTakeyoshiT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
81-90
|
|
pubmed:meshHeading |
pubmed-meshheading:21327925-Adult,
pubmed-meshheading:21327925-Aged,
pubmed-meshheading:21327925-Aged, 80 and over,
pubmed-meshheading:21327925-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:21327925-Ascites,
pubmed-meshheading:21327925-Ascitic Fluid,
pubmed-meshheading:21327925-Disease Progression,
pubmed-meshheading:21327925-Female,
pubmed-meshheading:21327925-Humans,
pubmed-meshheading:21327925-Male,
pubmed-meshheading:21327925-Middle Aged,
pubmed-meshheading:21327925-Neoplasm Recurrence, Local,
pubmed-meshheading:21327925-Paclitaxel,
pubmed-meshheading:21327925-Stomach Neoplasms,
pubmed-meshheading:21327925-Survival Rate,
pubmed-meshheading:21327925-Treatment Failure,
pubmed-meshheading:21327925-Treatment Outcome,
pubmed-meshheading:21327925-Waist Circumference
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
|
|
pubmed:affiliation |
Department of Surgery, Kinki University, Osaka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
